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      ABSTRACT
The purpose of this study is to formulate implant containing Clindamycin hydrochloride that
could  be  used  in  the  treatment  of  periodontitis.  The  implants  were  formulated  by using
biodegradable polymer, gelatin and sodium alginate with PEG 400 as a plasticizer. The drug
and  polymer  compatability  in  implants  were  studied  by  FT-IR  and  DSC.  There  was  no
interaction between the drug and polymer. The implant was evaluated for physicochemical
properties  such  as  weight  uniformity,  thickness,  content  uniformity,  %moisture  loss  and
surface pH. The result of physicochemical properties was uniform for all the formulations.
The in-vitro results showed that increase in the polymer concentration (70:30) prolong the
drug release upto 24hrs. Optimized formulation F7 release 84.90% of drug at the end of 24 th
hr  and  considered  as  a  best  formulation.  The  release  mechanism for  invitro  release  was
studied  by using  various  mathematical  models.  The  ‘n’ value  for  the  koresmeyer-peppas
equation  was  in  the  range  of  0.87-0.98  indicating  the  anamolous  behaviour  (non-fickian
release).  In-vitro  antibacterial  activity  was  carried  out  in  Staphylococcus  aureus  and
Enterobacter aerogen had an inhibitory effect after 24hrs of incubation. The stability studies
were carried out at room temperature, dark place and direct sunlight which does not shows
any significant change after one month.
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1. INTRODUCTION
 Novel drug delivery system (NDDS) has gained a considerable attention from the last
few decades. In the form of NDDS, an existing drug molecule can get a new life, thereby
increasing the market value, competitiveness and novelty in drug delivery. Implantable drug
delivery system (IDDS) is an example of such systems available for therapeutic use.
  Historically the subcutaneous implantation of drug pellets is known to be the first
biomedical  approach  aiming  to  achieve  the  prolonged  and  continuous  administration  of
drugs. This first generation of IDDS was produced by compressing drug crystals, with or
without a small fraction of pharmaceutical excipients into tiny, cylindrical solid pellets that
could be readily implanted into subcutaneous tissue1.
In 1861 Lafarge first introduced the concept of implantable systems for sustained drug
administration.  The  concept  was  later  used  to  produce  solid  implants  containing  steroid
hormones-initiating the use of pure drug with no added excipient. Sterile tablets consisting of
the highly purified drug, usually compressed without excipient  intended for subcutaneous
implantation in body tissue. The device thus prepared had a high degree of hardness and
virtually  zero  porosity.  Since  water  did  not  penetrate  the  matrix  drug  release  occurred
principally by surface dissolution. Due to the inherent poor solubility of steroid drugs this
method provided a good form of depot medication2.
The implantable therapeutic systems are mainly approached for
• Long term
• Continuous drug administration and
• Controlled release
 Over the years a number of approaches have been developed to achieve the controlled
administration of biologically active agents via implantation (or insertion) in tissues. These
approaches are outlined as follows1. 
I. Controlled drug delivery by diffusion process
A. Polymer membrane permeation controlled systems containing
1. Non porous membrane
2. Microporous membrane
3. Semipermeable membrane
B. Matrix diffusion controlled systems containing
1. Lipophilic polymers
2. Hydrophilic swellable polymers
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3. Porous polymers
C. Microreservoir dissolution controlled systems containing
1. Hydrophilic reservoir/ lipophilic matrix
2. Lipophilic reservoir/ hydrophilic matrix
II. Controlled drug delivery by activation process
A. Osmotic pressure activated
B. Vapour pressure activated
C. Magnetically activated
D. Phonophoresis activated
E. Hydration activated
F. Hydrolysis activated
III. Controlled drug delivery by feedback regulated process
A. Bioerosion regulated drug delivery
B. Bioresponsive drug delivery
  Most of the approaches listed above can be adopted to fabricate the systems for
controlled  release  of  biologically active  agents.  Polymers  of  both non-biodegradable and
biodegradable types can be used depending on the requirement.
Biodegradable polymers:
  Biodegradable systems have gained much popularity over non-degradable delivery
system,  as  they  are  eventually  absorbed  or  metabolized  and  excreted  by the  body.  This
alleviates  the  need  for  surgical  removal  of  the  implant  after  the  conclusion  of  therapy
increasing patient compliance.
Non-biodegradable polymers:
 These are inert in the environment use and serve essentially as a rate limiting barrier
to the transport and release of drug from the device. The major disadvantage is the implants
have  to  be  removed  surgically  once  the  conclusion  of  the  therapy  from  the  site  of
implantation since they are non- biodegradable.
1.1 Polymers used in the implants3
Carbochain polymers 
Polyethylene 
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Polypropylene 
Polytetrafluoroethylene 
Poly-α-cyanacrylates
Heterochain polymers
Poly (DL-lactide co-glycolide)
Polyurethanes 
Polylactic acid
Polyorthoester
Collagen 
Gellan 
Gelatin 
Mucopolysaccharides 
1.2 Ideal requirements of implantable drug delivery systems4
• Environmentally stable
• Biocompatible
• Sterile
• Biostable
• Improve patient compliance by reducing the frequency of drug administration over the
entire period of treatment.
• Release the drug in a rate-controlled manner that leads to enhanced effectiveness and
reduction in side effects.
• Readily retrievable by medical personnel to terminate medication.
• Easy to manufacture and relatively inexpensive.
1.3 Advantages of the implantable drug delivery system4
• Improved efficiency
• Very effective
• Small dose is sufficient to elicit the action
• Reduced side effects
• On-spot delivery
• Convenient therapy
• Plasma drug levels are continuously maintained in a therapeutically desirable range
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• Harmful side effects  from systemic administration can be reduced or  eliminated by
local administration from a controlled release system.
• Continuous small amounts of drug may be less painful than several large doses.
• Patient compliance is improved.
1.4 MECHANISM OF DRUG RELEASE FROM IMPLANTABLE DEVICES2
Drug  release  from  most  implantable  devices  is  controlled  by  any  one  of  six  different
mechanisms discussed below.
1.4.1 Diffusion controlled
These devices are based on Fick’s law of diffusion which states that the rate of transfer of
a  diffusing  substance  through  unit  area  of  a  section.  In  this  case  the  rate  of  release  is
controlled by diffusion of drug through a polymeric membrane. Diffusion-controlled devices
can be further classified into membrane-permeation controlled, matrix-controlled and micro
reservoir-dissolution controlled.
 Membrane-permeation controlled
In  membrane-permeation controlled devices  the drug reservoir  is  surrounded by a
membrane and because  of  the presence of  the two distinct  drug-reservoir  and membrane
phases  these  are  known as  heterogeneous  devices.  When the  device  containing a  highly
hydrophilic drug is placed in aqueous dissolution medium, water penetrates the coating and
dissolves  the  drug and  the  concentrated  drug  solution diffuse  out  through the  polymeric
membrane. The release rate of the drug is controlled by the diffusion rate of drug solution
through a spherical membrane permeation controlled system with saturated reservoir is given
by equation.
                                
dM
dt
=
4 piDk (C1C2)ab
ba    
Where,  
dM
dt  is related to the drug concentration in the matrix and the rate of polymer
erosion
D is the diffusivity of drug unit thickness of polymer 
 k is the partition coefficient (ratio of solubility of drug in the polymer divided by the
solubility of drug in the surrounding medium) of drug across the polymer membrane 
C1 is the concentration of drug inside the sphere 
C2 is the concentration of drug in the surroundings 
a is the inner radius of the coat and 
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b is the outer radius of the coat.
 Matrix controlled
In matrix-controlled devices the drug is uniformly distributed throughout the polymer
and hence these are known as homogenous devices. In the presence of dissolution medium
drug at the surface dissolves first and is released in the dissolution medium. In many cases
the  dissolved  drug  creates  a  depletion  boundary  separating  the  empty  or  drug-depleted
polymer from the drug loaded polymer matrix. The drug release rate is controlled by the
diffusivity barrier provided by at the empty matrixes which increase in thickness with time.
For a matrix system that is exposed to the dissolution medium on all the sides the surface area
of the inward-moving depletion boundary decrease resulting in a decrease  in drug release
rate which depends on the device geometry.
 Micro reservoir dissolution-controlled
In these devices the drug reservoir is made of a suspension of solid drug particles in
an  aqueous  solution  of  a  water  miscible  polymer  forming  millions  of  microscopic  drug
reservoirs  in  a  polymer matrix  the device  is  coated  with a  rate-controlling membrane to
further modify the drug release.
.
1.4.2 Chemically controlled
Chemically  controlled  drug  delivery  systems  regulate  the  drug  release  rate  by  a
chemical  reaction  with  the  polymer.  The  principal  advantage  is  that  in  contrast  to  a
nonbioerodible system the polymer is dissolved and absorbed by the body. However the fate
of these polymeric products in the body must be carefully observed and rigorous testing is
required  to  confirm  the  safety  of  the  polymer.  The  two  predominant  mechanisms  for
chemically controlling drug release are bioerosion and pendent chain.
 Bioerosion
The bioerosion or  biodegradation systems involve breakdown of  the polymer into
small  water  soluble  molecules.  Bioerosion-controlled  devices  are  matrix  controlled  with
uniform drug distribution inside the polymer. As the polymer is broken down water comes in
contact  with  the  drug leading to  its  dissolution  and release.  Depending on water-soluble
components water may penetrate throughout the device or come in contact only with the
surface. In the former case polymer erosion starts throughout the matrix: these devices are
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known as bulk eroding. On the other hand if the polymer is hydrophobic and water does not
penetrate inside the device, erosion only on the surface; these devices can be called surface
eroding.  The  drug  rate  from  a  surface  eroding  polymeric  matrix  with  uniform  drug
distribution is given by eq.
                                   
dM
dt
=ks
 
Where, K is a constant, 
dM
dt  is  related to the drug concentration in the matrix  and the rate of polymer
erosion 
S is the surface area of the system. 
 Pendent chain
The  other  mechanism for  chemically  controlled  release  of  drug  is  known  as  the
pendent-chain  system  where  the  drug  is  attached  to  the  polymer  backbone  by  a  labile
chemical linkage. In the presence of water or enzymes the labile linkage breaks the drug. The
pendent chain may be water soluble or insoluble; a water backbone may serve as a drug
carrier to a specific cell or organ where the drug is released by metabolism. Insoluble pendent
chains  serve as a depot from which the drug slowly released.
1.4.3 Solvent activated
Solvent-activated  system release  active  agents  because  of  controlled  penetration  of  a
solvent into the device; they can be controlled by swelling or osmotic pressure.
 Swelling controlled
Swelling-  controlled  systems  are  similar  to  matrix-type  devices  except  that  the
dispersed drug is immobilized inside a glassy polymer and therefore there is no diffusion of
drug. When this device is placed in water the outer polymer region begins to swell, resulting
in relaxation of the polymer chains. This allows the locked drug to diffuse outward. Therefore
two fronts are observed: one moving inward, separating the polymer in the glassy state from
the rubbery state and the second moving outward separating the swollen rubbery polymer
from the surrounding aqueous medium. The drug release is determined by the rate relaxation
of the chains that unlock the drug.
 Osmotically controlled
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In osmotically controlled system an osmotically active agent such as water soluble
salt  is  placed  inside  a  rigid  semi  permeable  housing,  which  is  separated  from the  drug
compartment by a movable partition.  The semi permeable housing draws water inside by
osmosis, leading to an increase in volume and exertion of pressure on the movable partition.
The partition, in turn pushes the drug out of the compartment through a delivery orifice or
cannula. Thus, the drug delivery rate is controlled by the mass movement of water across the
permeable membrane.
1.4.4 Externally regulated
These  systems  have  the  important  advantage  that  the  drug-delivery  rate  can  be
externally increased on demand ever after the device has been implanted. Four predominant
techniques have been evaluated with externally modulated implant: magnetically controlled,
ultrasonically activated, thermally activated and electrically controlled.
 Magnetically controlled
In  magnetically controlled drug-delivery systems the drug and magnetic  beads are
uniformly dispersed inside semi elastic polymer matrix made of a nonbiodegradable polymer
such as ethylene-vinyl acetate copolymer (EV Ac). When the device is placed in dissolution
medium the drug release follow matrix diffusion control. However, when the device is placed
in a magnetic field, the magnetic beads attempt to a align with the applied magnetic field
including a torque on the magnet and a slight rearrangement of the polymer. In an oscillating
magnetic field, the beads tend to oscillate compressing and expanding the polymer in the
process.
 Ultrasonically activated
In these systems the drug is uniformly distributed inside a polymer and an external
ultrasonic field is applied to activate drug release. They have been evaluated for both non
biodegradable polymers (EVAc) and biodegradable polymers [polyesters, polynanhydrides,
polyglycolides,  polylactides  and  sebacic  acid].  In  the  case  of  biodegradable  polymers
application of  ultrasound increases the drug release as well as the polymer degradation rate.
In both the biodegradable and nonbiodegradable polymer systems the drug release rate was
controlled by the intensity, frequency and duration of the ultrasound.
 Thermally activated
A series of thermosensitive hydrogels that show significant swelling changes in water
in response to temperature have been prepared and evaluated. These polymers responded to
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temperature change based on the Flory-Huggins theory that a change in temperature affects
hydrogen bonding which in turn, affects swelling. A linear correlation is observed between
the diffusion coefficient for entrapped drug and polymer swelling. 
 Electrically controlled
Electrically  controlled  systems  provide  drug  release  by  the  action  of  an  applied
electric field on a rate-limiting barrier membrance or a solute thus modulating its transport
across  it.  Grimshaw reported four  different  mechanisms for  the transport  of proteins  and
neutral solutes across hydrogel membranes:
• Electrically and chemically induced swelling of a membrane to alter the effective pore
size and permeability
• Electrophoretic augmentation of solute flux within a membrane
• Electroosmotic augmentation of solute flux within the membrane and
• Electrostatic partitioning of charged solutes into charged membrane.
1.4.5 Self-regulated
These are biofeedback-controlled system, where the drug release rate is dependant on
the body’s need for the drug at a given time. From a therapeutic viewpoint these systems may
come  close  to  duplicating  the  release  from  a  gland  such  as  the  pancreas.  A variety  of
mechanisms have been employed to obtain self-regulated delivery.
 Ionic strength and pH responsive
These devices take advantage of the fact that polymers containing weakly acidic or
basic side groups develop a charge in alkaline or acidic pH respectively. In a cross-linked
water-insoluble  polymer,  this  results  in  water  uptake  and  corresponding  swelling  of  the
polymeric membrane with opening of molecular pores and increased drug release rate. 
 Glucose responsive
Glucose Oxidase catalyses a reaction between glucose and oxygen in the body fluids
to form gluconic acid, which reduces the pH of the microenvironment. The insulin-release
systems based on glucose Oxidase utilize this drop in pH to trigger an increased release.
 Urea responsive
The  device  of  disk  containing  hydrocortisone  incorporated  into  a  biodegradable
polymer  with pH dependent degradation. This disk is coated with a hydrogen containing
immobilized urease. In physiological- buffer base line hydrocortisone is released due to the
hydrolysis of the polymer and diffusion of drug. In the prevalence of urea the enzyme urease
increases the pH of microenvironment by converting urea into ammonium bicarbonate and
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ammonium hydroxide.This increase in pH results  in results in increased hydrolysis of the
biodegradable polymer and increased hydrocortisone release.
1.5 NON-DEGRADABLE AND BIODEGRADABLE IMPLANT SYSTEMS
1.5.1 Non-degradable implant systems
 
Figure 1.1: Matrix system showing diffusion of the drug across the polymer
        There are several types of nondegradable implantable drug delivery systems available in
the market place today, but the nondegradable matrix system and reservoir systems are the
two most common forms.
In  the  polymeric  matrix  system,  the  drug  is  dispersed  homogeneously,  inside  the
matrix material. Slow diffusion of the drug through the polymeric matrix material provides
sustained release of the drug from the delivery system.
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Figure 1.2: Reservoir systems showing diffusion of the drug across the polymer
The reservoir-type consists of a compact drug core surrounded by a permeable nondegradable
membrane whose thickness and permeability properties can control the diffusion of the drug
into the body5. The release kinetics of drug from this system suggest that if the concentration
of  the  drug  within  the  reservoir  is  in  constant  equilibrium with the  inner  surface  of  the
enclosed membrane, the driving force for diffusional release of the agent is constant and zero-
order  release  kinetics  of  the  drug  from the  delivery  system  is  obtained.  This  system  is
nondegradable.
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1.5.2 Bio degradable implant systems
           Biodegradable systems have gained much popularity over nondegradable delivery
systems.  The  major  advantages  of  biodegradable  systems  include  the  fact  that  the  inert
polymers, used for the fabrication of the delivery system, are eventually absorbed or excreted
by the body. This alleviates the need for surgical removal of the implant after the conclusion
of therapy thereby increasing patient acceptance and compliance6.
            However,  developing biodegradable systems is  a more complicated task than
formulating  nondegradable  systems.  When  fabricating  new  biodegradable  systems,  many
variables  must  be  taken  into  consideration.  For  instance,  the  degradation  kinetics  of  the
polymer, in vivo, must remain at a constant rate to maintain sustained release of the drug.
Many factors can affect the rate of degradation of the polymer in the body. Alterations in
body pH or temperature can cause a transient increase or decrease in the degradation rate of
the  system.  The  surface  area  of  the  delivery  system also  plays  an  important  role  in  its
degradation7. As the system is eroded, the surface area of the implantable system decreases. 
1.6 THERAPEUTIC APPLICATIONS2
• Ocular disease
Ocusert containing pilocarpine base and alginic acid in a drug reservoir surrounded by
a release-rate controlling ethylene-viny1 acetate membrane. The ocusert system provides an
initial burst followed by a near zero order delivery of pilocarpine at 20 or 40 µg/h for a period
of seven days.
• Contraception
Norplant  a  subdermal  implant  for  long-term  delivery  of  the  contraceptive  agent
levonorgestrel gas recently been approved for marketing by the FDA. The device consists of
six silicone membrane capsules each containing about 36 mg of levonorgestel. Cumulatively
the six capsules deliver about 70 µg/day at about 800 days. 
• Dental allocation
 Sustained-release fluoride delivery stannous fluoride was incorporated into different
dental cements. The device, about 8 mm long and containing 42 mg of fluoride in the core
was attached to the buccal surface of the maxillary first molar and designed to release 0.5 mg
of fluoride per day for 30 days. 
• Immunization
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The concept here is to provide pulsatile of continuous administration of the antigen
over a prolonged time period. For example, immunization efficiency of ethylene-vinyl acetate
copolymer pellets containing bovine serum albumin as model antigen. 
• Cancer
Silicone  rod  implants  similar  to  those  used  for  delivery  of  levonorgestrone,
testosterone propionate or ethinyl estradiol were used in patients with prostate cancer.
Lupron  depot  is  an  implantation  system  providing  one  month  depot  release  of
leuprolide acetate a synthetic analogue of the gonadotropin releasing hormone (GhRH). The
implant  consists  of  biodegradable  microspheres  prepared  from  polylactic  –  glycolic
copolymer  at  50:50  composition  containing  10%  leuprolide  acetate  for  the  treatment  of
prostate cancer 
• Narcotic antagonists
Naltrexone freebase and its hydrochloride or the pamolate acid salt has been prepared
in a variety of polymers and dosage forma for prolonged narcotic antagonist activity. Though
in vitro delivery of up to 50 day has been achieved by some of the systems in vivo duration of
release has been shorter.
1.7 DIFFERENT TYPES OF IMPLANTS
 Brain implants8
Brain implants, often referred to as  neural implants, are technological devices that
connect directly to a biological subject's brain- usually placed on the surface of the brain or
attached to the brain's cortex. A common purpose of modern brain implants and the focus of
much current research is establishing a biomedical prosthesis circumventing areas in the brain
that have become dysfunctional after a stroke or other head injuries. This includes sensory
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substitution, e.g. in vision. Other brain implants are used in animal experiments simply to
record brain activity for scientific reasons. Some brain implants involve creating interfaces
between neural systems and computer chips.
 Microchip implants9
A human microchip implant is an integrated circuit device or RFID (radiofrequency
identification) transponder encased in silicate glass and implanted in the body of a human
being. A subdermal  implant  typically contains a  unique ID number that  can be linked to
information  contained  in  an  external  database,  such  as  personal  identification,  medical
history, medications, allergies, and contact information.
 Microdermal implant10
Micro dermal implants are a form of body modification which gives the anaesthetic
appearance  of  a  transdermal  implant,  but  without  the  complications  of  the  much  more
complicated  surgery  associated  with  transdermal  implants.  Microdermal  implants  can  be
placed practically anywhere on the surface of the skin on the body.
 Contraceptive implants11
Norplant is implanted under the skin in the upper arm of a woman, by creating a small
incision and inserting the capsules in a fan-like shape. Insertion of Norplant usually takes 15
minutes and the capsules can sometimes be seen under the skin, although usually they looks
like small veins.
 Retinal implants12
A retinal implants is a biomedical implant technology that it meant to partially restore
useful vision to people who have lost due to a degenerative eye conditions such as retinitis
pigmentosa  or  macular  degeneration.  There  are  two  types  of  retinal  implants:  epiretinal
implant (on the retina) and subretinal implant (behind the retina).
 Dental implants13
A dental implant is a "root" device, usually made of titanium, used in dentistry to
support restorations that resemble a tooth or group of teeth to replace missing teeth. All dental
implants  placed  today are  root-form endosseous  implants,  i.e.,  they appear  similar  to  an
actual  tooth  root  and  are  placed  within the  bone.  The  bone  of  the  jaw  accepts  and
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osseointegrates with the titanium post. Osseointegration refers to the fusion of the implant
surface with the surrounding bone. Dental implants will fuse with bone; however they lack
the periodontal ligament, so they will feel slightly different than natural teeth during chewing.
Dental implant is available as patches for the bacterial infections in order to prevent
the growth of micro-organisms.
DENTAL IMPLANTS
Dental  implants  can be used  to  support  a  number of  dental  prostheses,  including
crowns,  implant-supported bridges or  dentures14.  They can also be used as anchorage for
orthodontic  tooth  movement.  The  use  of  dental  implants  permits  unidirectional  tooth
movement without reciprocal action.
Dental implants are not susceptible to dental caries and other bacterial infections but
they can develop a condition called peri-implantitis. This is an inflammatory condition of the
mucosa and/or bone around the implant which may result in bone loss and eventual loss of
the implant. The condition is usually,  but  not always,  associated with a chronic infection.
Peri-implantitis is more likely to occur in heavy smokers, patients with diabetes, patients with
poor oral hygiene and cases where the mucosa around the implant is thin15.
Dental  diseases may affect the teeth or the gums or other tissues and parts of the
mouth. Dental diseases can cause much more serious problems than a toothache; they can
affect our ability to chew, smile, or speak properly. Their severity may range from a simple
apthous ulcer, to a common tooth cavity, or up to a deadly oral cancer. These are among the
most  common diseases  in  humans  and  include  dental  caries,  gingivitis,  periodontitis  and
many more oral conditions16.
1.9 PERIODONTAL DISEASES17
Periodontal diseases are generally divided into two groups
• Gingivitis , which causes lesions (inflammatory abnormalities) that affect the gums.
• Periodontitis , which damages the bone and connective tissue that supports the teeth.
A periodontal disease is caused by bacteria. Even in healthy mouth, the sulcus is teeming
with bacteria, but they tend to be harmless varieties. Periodontal diseases usually develops
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because of two events in the oral cavity: an increase in bacteria quantity and a change in
balance of bacterial types from harmless to disease-causing bacteria.
Periodontitis
Periodontitis occurs when the gum tissues separate from the tooth and sulcus, forming
periodontal pockets. Periodontitis is characterized by:
• Gum inflammation, with redness and bleeding
• Deep pockets (greater than 3 mm in depth) that form between the gum and the tooth.
• Loose teeth, caused by loss of connective tissue structures and bone.
Periodontal treatment approaches can basically be categorized as:
• Non-surgical  approaches-  Scaling and root  planning,  which may include the use of
topical or systemic antibiotics.
• Surgical approaches- Periodontal surgical techniques include flap surgery (periodontal
reduction), bone grafts and guided tissue regeneration.
• Restorative procedures- Crown lengthening is an example of a restorative procedure
that may be performed for cosmetic reasons or to improve function. For patients who
have already lost teeth to advanced periodontitis, dental implants are another options.
Non- Surgical treatment
Scaling and root planning is a deep cleaning to remove bacterial plaque and calculus
(tartar). It is the cornerstone of periodontal disease treatment and the first procedure a dentist
will  use.  Scaling involves  scraping tartar  from the  above and  below the gum line.  Root
planning smoothes the root surfaces of the teeth.
At the time of scaling and root planning, the antibiotics are recommended because of
the risk of developing antibiotic-resistant infections. Antibiotics for periodontal disease come
in various forms. They may be taken as a prescription mouthwash rinse, or placed topically as
dissolving gels, threads or microchips into the periodontal pockets.
Nonsurgical  periodontal  therapy  is  used  to  delay  repopulation  of  pathogenic
microorganisms  by  controlling  the  supragingival  bacterial  plaque  and  by  disrupting  or
removing the subgingival gram-negative flora.
The  clinical  outcome  of  periodontal  treatment  is  improved  if  specific  microbial
pathogens are eradicated from the tissues18. Because local scaling and root planning alone
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cannot achieve this predictably, mechanical treatment has been combined with the delivery of
either  topical  or  systemic  antimicrobial  therapy19-21.  Agent  used  in  this  situation  include
amoxicillin, clindamycin, metronidazole, tetracycline and doxycycline. Some antibiotics have
been shown to have anti-inflammatory properties that are independent of their antimicrobial
activities22, 23.
In addition to a direct antibacterial effect on ribosomal nits, clindamycin has a number
of unique pharmacologic features that enhance its clinical efficacy. Clindamycin is the only
proven  antibiotic  that  reduces  the  adherence  of  bacteria  to  the epithelial  cell  of  mucosal
surfaces and inhibits the expression of virulence factors.
Clindamycin  is  known  to  have  a  very  favourable  spectrum  of  activity  against
anaerobic  infections.  Its  antimicrobial  spectrum also  includes  gram-positive  cocci,  gram-
positive and gram-negative anaerobes and certain protozoa. Clindamycin has been considered
a suitable antimicrobial  for  the management  of  periodontal  infection.  Clindamycin in  gel
form have been used in the treatment of periodontal diseases24. When it was given in gel form
its bioavailablity reduces and number of doses increases. Normally clindamycin half-life is 2-
3 hrs25. In the present study, in order to increase its half-life as well as to reduce the dose,
implant has been developed by using the biodegradable polymers.
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2. REVIEW OF LITERATURE
2.1 CLINDAMYCIN24
Clindamycin is a lincosamide antibiotic which inhibits the growth of the microorganisms.
Clindamycin hydrochloride is the hydrated hydrochloride salt of clindamycin, a substance
produced by the chlorination of linocomycin. It  has a potency equivalent  to not less than
800µg of clindamycin (C18H33ClN2O5S) per mg.
Table 2.1: Characteristics of Clindamycin Hydrochloride
Generic name Clindamycin Hydrochloride
Synonyms Anti-clindamycin, Cleocin, Dalacin
Chemical name L-threo-α-D-galacto-octopryanoside  methyl
7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-
propyl-2-pyrrolidinyl)-carbonyl)amino]-1-
thio-(2S-trans) monohydrochloride
Molecular formula C18H33ClN2O5S.HCl
Molecular weight 461.45
Appearance Yellow, amorphous solid
                              
                                 
                                        Figure 2.1 Clindamycin Hydrochloride
Mechanism of action
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  Clindamycin  has  a  bacteriostatic  effect.  It  is  a  bacterial  protein  synthesis  inhibitor  by
inhibiting ribosomal translocation26. It binds to 50S rRNA of the bacterial ribosome subunit27.
It also inhibit the binding of amino-acyl transfer RNA or the translocation of messenger RNA
Clindamycin contains a basic pyrrolidene ring attached to a sugar group through an amide
bond. The replacement of the hydroxyl group in lincomycin to a chloride atom increases the
lipophilicity  and  therefore  clindamycin  shows  a  better  absorption  and  penetration  into
bacterial cells.
Figure 2.2: Mechanism pathway of Clindamycin hydrochloride28, 29
Indication 25
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It  is used for the treatment of serious infections caused by susceptible anaerobic bacteria,
including  Bacteroides  spp.,  Peptostreptococcus,  anaerobic  Streptococci,  Clostridium  spp.,
and microaerophilic Streptococci. It may be useful in polymicrobic infections such as intra-
abdominal or pelvic infections, osteomyelitis, diabetic foot ulcers, aspiration pneumonia and
dental infections. It  can also be used to treat MSSA (Methicillin sensitive Staphylococcus
aureus) and respiratory infections caused by S. pneumoniae and S. pyogenes in patients who
are intolerant to other indicated antibiotics or who are infected with resistant organism. It may
be used vaginally to treat vaginosis caused by  Gardnerella vaginosa. Clindamycin reduces
the toxin producing effects of  S. aureus and  S. pyogenes and as such, may be particularly
useful for treating necrotizing fasciitis. 
Table 2.2: Physicochemical and biopharmaceutics parameters of Clindamycin Hydrochloride25
Physicochemical parameters
Storage Store at controlled room temperature 20ºC to
25ºC (68º to 77ºF)
Solubility Soluble in water, pyridine, ethanol and DMF
(N,N-dimethlyformamide)
Melting point 142ºC
Biopharmaceutical parameters
Bioavailability 90% (Oral), 4-5%(Topical)
Absorption Rapidly  absorbed  after  oral  administration
with  peak  serum  concentrations  observed
after about 45 minutes. Absorption of an oral
dose is virtually complete (90%) 
Protein Binding 92-94%
Metabolism Hepatic
Half life 2-3Hrs
Excretion Excreted  in  the  urine  and  in  the  feces;  the
remainder  is  excreted  as  bioinactive
metabolites
Adverse reaction30
 Gastrointestinal  - Abdominal pain,  nausea,  vomiting, diarrhea,  colitis,  esophagitis
and esophageal ulcer.
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Hypersensitivity Reactions  - Maculopapular rash and urticaria have been observed
during  drug  therapy.  Rare  instances  of  erythema  multiforme,  some  resembling  Stevens-
Johnson syndrome, have been associated with clindamycin. 
 Liver - Jaundice and abnormalities in liver function tests have been observed during
clindamycin therapy.
Skin and Mucous Membranes - Pruritus, vaginitis and rare instances of exfoliative
and vesiculobullous dermatitis have been reported. Rare cases of toxic epidermal necrolysis
have been reported during post-marketing surveillance.
Hematopoietic  -  Transient  neutropenia  (leukopenia)  and  eosinophilia  have  been
reported. Reports of agranulocytosis and thrombocytopenia have been made. 
 Renal  - Although no direct  relationship of clindamycin to renal  damage has been
established, renal dysfunction as evidenced by azotemia, oliguria and/or proteinuria has been
observed in rare instances.
Musculoskeletal - Rare instances of polyarthritis have been reported.
Nervous System - Dysgeusia has been reported during post-marketing surveillance.
Interactions
  Erthyromycin      -    Antagonistic effect
  Kaolin/ Pectin     -     Decreased GI absorption of clindamycin
  Hormonal contraceptives- Decreased contraceptive efficacy
  Neuromuscular blockers - Enhanced neuromuscular blockade
Uses
• Acne
• Bacterial vaginosis
• As prophylaxis in bacterial endocarditis
• Other serious anaerobic infection
Dosage form
  Capsule   75mg, 150mg, 300mg
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  Gel, topical 1%   30gm, 60gm or 40ml, 75ml
  Granules for oral solution  75mg/5ml (100ml)
  I.V   300mg (50ml), 600mg (50ml), 900mg (50ml)
  Lotion 1%    60ml
  Solution, topical 1% 30ml, 60ml
  Vaginal suppository 100mg
Dosage
 For Severe infection caused by sensitive organisms
Adults: 300 to 450mg p.o q 6hrs pr  1.2 to 2.7ml/day i.m or i.v two to four
equally divided doses
Children: 16 to 20mg/kg/day (Hydrochloride) in 3 to 4 equally divided doses or
13 to 25mg/kg/day p.o (Palmitate HCl) in 3 to 4 equally divided doses.
Neonates younger than 1 month: 15 to 20mg/kg/day i.m or i.v in 3 to 4 equally
divided doses.
 Acute pelvic inflammatory disease
         Adults: 900mg i.v q 8hrs (given with gentamicin)
 Acne vulgaris
Adults and children older than age 12. Apply a thin film of topical gel, lotion or
solution locally to affected area b.i.d.
 For prevention of endocarditis:
Adults: 300 mg orally 1 hour before surgical procedure; then 150 mg 6 hours after
initial dose.
Children: 10  mg/kg  (not  to  exceed  adult  dose)  orally  1  hour  before  surgical
procedure; then 5 mg/kg 6 hours after initial dose.
2.2 POLYMER PROFILE                  
 2.2.1 GELATIN31
     Gelatin is a generic term for a mixture of purified protein fractions obtained either by
partial acid hydrolysis (type A gelatin) or by partial alkaline hydrolysis (type B gelatin) of
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animal collagen. The protein fractions consist almost entirely of amino acids joined together
by amide linkages to form linear polymers.
Synonyms: Byco; Cryogel; Gelatine, Instagel, Solugel
Molecular weight: 15 000- 2 50 000
Functional categories: Coating agent, film former, gelling agent, suspending agent, tablet
binder, viscosity-increasing agent
Pharmaceutical Specifications
        Test                                                           Ph Eur 2005
 pH                                                                     3.8-7.6
 Loss of drying                                                   15%
 Isoelectric point                                                 6.0-9.5 (Type A), 4.7-5.6 (Type B)
Typical properties
        Acidity/alkalinity: For a 1%w/v aqueous solution at 25ºC
pH = 3.8-6.0 (Type A)
pH = 5.0-7.4 (Type B)
       Density 
1.325 g/cm3 for type A
1.283 g/cm3 for type B
       Isoelectric point
7-9 for type A
4.7-5.3 for type B
      Moisture content: 9-11% 
 Solubility:
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     Practically insoluble in acetone, chloroform, ethanol (95%), ether and methanol. Soluble
in glycerine, acids and alkalis, although strong acids or alkalis cause precipitation. Gelatine is
soluble in hot water, forms a jelly or gel on cooling at 35-40ºC.
Application in pharmaceutical formulation or technology
Gelatin is used as a biodegradable matrix material in an implantable delivery system.
Gelatin  is  also used for  the microencapsulation of  drugs,  preparation of  pastes,  pastilles,
pessaries and suppositories. In addition, it is used as a tablet binder and coating agent and as a
viscosity for solutions and semisolids. 
        
                                   
2.2.2 SODIUM ALGINATE32
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       Sodium alginate consists of  sodium salt of alginic acid, which is a mixture of polyuronic
acids composed of residues of D-mannuronic acid and L-guluronic acid.
Synonyms: Algin, E401, Kelcosol, Keltone, Protanal, Sodium polymannuronate
Functional category: Stabilizing agent, suspending agent,  tablet and capsule disintegrant,
tablet binder, viscosity-increasing agent.
Pharmaceutical specifications
     Test USPNF 23
Microbial limits 200/g
Loss of drying 15.0%
Ash 18.0-27.0%
Assay 90.8-106.0%
Typical properties
Acidity/alkalinity: pH~7.2 for a 1%w/v aqueous solution
Solubility:  
Practically insoluble in ethanol (95%), ether, chloroform, and ethanol/water. Slowly soluble
in water and forms a viscous colloidal solution.
Viscosity (dynamic):  
Typically, a 1%w/v aqueous solution at 20ºC, will have a viscosity of 20-400 mPas (20-400
cP). Viscosity may vary depending upon concentration, pH, temperature or the presence of
metal ions.
Applications in pharmaceutical formulation or technology
Sodium alginate is used in tablet formulations as a binder and disintegrant, it has been used as
a diluents in capsule formulations. Sodium alginate has also been used in the preparation of
sustained release oral formulations, since it can delay the dissolution of a drug from tablets,
capsules and aqueous suspensions.
2.3 REVIEW OF LITERATURE
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H.A.Khan et al 33, Tamsulosin biodegradable PLGA in-situ implant was formulated and the
invitro release study was performed. The effect of drug loading and the effect of excipients on
the  release  pattern  were  studied.  This  system is  prepared  by dissolving  a  biodegradable
polymer DL-poly (lactide-co-glycolide) 70K in biocompatible solvent, dimethyl sulfoxide.
Two types of implants were prepared such as implants containing tamsulosin hydrochloride
and tamsulosin hydrochloride with biocompatible excipients such as  tween 20, tween 60,
span 20, span 80, chremophore EL or chremophore RH 40. In vitro dissolution studies were
performed in static condition using phosphate buffer (pH 7.4) to observe the release of drugs
from  these  implants  for  10  days.  Formulation  containing  only  tamsulosin  hydrochloride
showed that the release rate of drug was 64.51%, 70.64%, 74.08%, 76.12% and 80.05%. It
can be concluded that the release rate of drug increases with increasing drug concentrations.
The other formulation containing tamsulosin with excipients showed that the release rate was
74.70%, 75.14%, 60.03%, 63.83%, 70.82% and 76.43% against same conc. of drug (8.7% of
drug) but different excipients such as tween 20, tween 60, span 20, span 80, chremophore EL
and cremophore RH 40 respectively. It can be concluded that excipient lowers the release rate
of the drug and may prolong the activity and overall release kinetics.
Heba  A  Gad  et  al34, In  Situ  implants  containing  Doxycycline  hydrochloride  and/or
Secnidazole  was  formulated  to  treat  the  periodontitis  by  direct  periodontal  intrapocket
administration. Biodegradable polymers [poly (lactide) (PLA) and poly (lactide-co-glycolide)
(PLGA)], each polymer in two concentrations 25%w/w, 35%w/w were used to formulate the
in-situ  implants.  The  rheological  behaviour,  in  vitro  drug  release  and  the  antimicrobial
activity  of  the  prepared  implants  were  evaluated.  Increasing  the  concentration  of  each
polymer increases the viscosity and decreases the percent of the drug released after 24hrs.
PLA implants showed a slower drug release rate than PLGA implants in which the implants
composed of 25% PLGA showed the fastest drug release.
Ananta  Choudhury  et  al35, Buccoadhesive  film  of  Ciprofloxacin  hydrochloride  was
developed  and  in-vitro  parameter  was  studied.  Films  were  formulated  using  different
concentration of hydroxypropyl methyl cellulose and polyvinyl alcohol. The prepared films
were  subjected  to  different  evaluation  like  weight  determination,  thickness,  surface  pH,
folding endurance, swelling index, mucoadhesive time, mucoadhesive strength, drug content,
in-vitro drug release study, ex-vivo release study and release kinetic behavior. From the result
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it was conclude that all prepared films having desire flexibility and mucoadhesive properties,
along with that they shows good in-vitro and ex-vivo drug release performance. Drug release
from the films follows desire sustained release phenomenon as needed in buccoadhesive drug
delivery.
M.G.Ahmed et  al36, Chitosan strips  containing Gatifloxacin (10%,  20% and 30% to the
weight of polymer) were prepared by solution casting method using 1% v/v acetic acid in
water. The  strips containing 30% gatifloxacin were cross-linked by exposing to the vapours
of 2% v/v glutaraldehyde in water intended to extend the release. The prepared films were
evaluated for their thickness, content uniformity, weight variation, tensile strength, hardness
and  in-vitro dissolution.  Macroscopical  features  revealed  that  drug  was  dissolved  in  the
polymer  matrix  rather  than  dispersing.  The  average  weight  and  thickness  of  both  the
crosslinked and uncross-linked  strips  were  uniform.  There was  a reduction  in  the tensile
strength and increase in hardness when the films were cross-linked. Static dissolution studies
showed a burst release initially followed by a progressive fall in the release of the drug and
extended upto 19 days once the strip was cross-linked. Release kinetics of gatifloxacin from
chitosan strips followed the higuchi’s diffusional model and also showed zero order release
profile.
Manoj kumar et al37, Periodontal films containing metronidazole were prepared by solvent
casting technique using ethyl cellulose, hydroxyl propyle cellulose and eudragit RL-100 with
dibutyl phthalate and polyethylene glycol 400. The films were evaluated for their thickness
uniformity,  folding endurance,  weight  uniformity,  content uniformity,  tensile strength and
surface pH. Data of in-vitro release from films were fit  to different equations and kinetic
models to explain release kinetics. Hixon-crowell, Higuchi and Korsmeyer-Peppas models
were  used  to  fit  the  in-vitro  release  data.  Formulation  with  high  concentration  of  ethyl
cellulose released 94.18% of the drug at the end of 120hrs and was more sustained with first
order  release  kinetics.  From  the  result,  it  was  concluded  that  metronidazole  could  be
incorporated in a slow release device for the treatment of peridontitis.
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N.Udupa  et  al38, Dental  implants  of  doxycycline  hydrochloride  and  tinidazole  were
formulated  using  a  biodegradable  carrier  poly  (ε-caprolactone),  for  the  treatment  of
peridontitis. The in-vitro drug release pattern and stability of these devices were studied. The
formulations showed an initial burst release followed by more sustained release of the drugs
throughout the period of study (42 days). The stability of the drug were shown a marked
improvement by formulating them in polymer matrix.
Varinder kumar et al39, Mucoadhesive buccal patches containing venlafaxine were prepared
using the solvent casting method. Chitosan and pectin were used as bioadhesive polymer at
different  ratios.  The  patches  were  evaluated  for  their  physical  characteristics  like  mass
variation, drug content uniformity, folding endurance, surface pH, and in vitro drug release,
in vitro buccal permeation study, ex vivo bioadhesion strength and ex vivo mucoadhesion
time. Patches exhibited controlled release and releases the entire contents with a period of 10
hrs.  Incorporation  of  PVP K-30 generally enhances  the  release  rate.  Swelling index  was
proportional  to  the  concentration  of  chitosan.  Drug  with  1:4  (chitosan:pectin)  polymer
showed satisfactory bioadhesive strength of 17.53 ± 0.47 g, and ex vivo mucoadhesion time
of 10.32hrs.  The surface pH of  all  batches  was within ± 0.4  units  and thus no mucosal
irritation is expected. Patches containing 1:4 of chitosan and pectin had higher bioadhesive
strength with sustained drug release as compared to patches with other ratios of polymer. The
optimized patch demonstrated good in vitro and ex vivo results.
G.L.Prabushankar et  al40, Levofloxacin dental  films for  periodontitis were formulated  by
solvent  casting  technique  using  ethyl  cellulose  and  other  copolymers  in  chloroform:
dichloromethane (1:1) solvent with dibutyl phthalate and PEG 400. The films were evaluated
for  their  thickness  uniformity,  folding  endurance,  weight  uniformity,  content  uniformity,
tensile strength, surface pH, and in vitro antibacterial activity. In vitro release from films was
fit  to different  equations and kinetic models to reveal  release kinetics.  The R2 values are
higher for Higuchi’s model compared to Hixson Crowell cube root law for all the films and
the release from all  the films followed diffusion rate.  Formulation with eudragit  RL-100
released 99.74% of drug at the end of tenth day and was considered as best formulation. . In
vitro antibacterial activity was carried out on S. aureus and E.coli was found to be effectively
higher in 48hrs and then decline at 96hrs. 
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V.S.  Mastiholimath  et  al41, Ornidazole  dental  implants  for  the  treatment  of  periodontal
diseases was prepared by using solvent casting technique using hydroxyl propyl cellulose,
hydroxyl methyl cellulose, eudragit RL-100 and ethyl cellulose with dibutyl phthalate . The
physicochemical parameters like thickness, weight variation, content uniformity and release
characteristic  were evaluated.  The drug release  was  initially high on day one to  achieve
immediate therapeutic level of drug in periodontal pocket followed by marked fall in release
by day two with progressive moderate release profile to maintain therapeutic level following
anomalous transport mechanism. Formulation with ethyl cellulose released 97.07% of drug at
the end of 120hrs and was considered as best formulation. In vitro antibacterial activity was
carried out on Streptococcus mutans and had an inhibitory effect upto 96hrs.
Rao.K.Purushotham et  al42, Diclofenac  sodium  biodegradable  drug  implant  for  speedy
fracture healing was formulated in varied ratios of gelatin and sodium alginate  70:30, 80:20
and 90:10% w/w by heating and congealing method. The implants were evaluated for content
uniformity,  thickness,  weight variation,  IR  and invitro  release studies.  The implants  gave
uniform result  for  thickness,  weight  variation  and drug content.  From the invitro  release
studies,  it  was concluded that  subdermal implants containing 90:10%w/w gelatin:  sodium
alginate were found to produce the most satisfactory drug release of 98.41% in 144 hours.
M.G.Ahmed  et  al43, Chitosan  based  Ciprofloxacin  and  Diclofenac  film  for  peridontitis
therapy  was  prepared  by  solvent  casting  method.  Some  of  the  drug  loaded  films  were
crosslinked  with  2%  glutaraldehyde  for  2  and  4hrs.  The  films  were  evaluated  for  their
physicochemical  properties  including  weight  variation,  thickness,  tensile  strength,  invitro
release and antibacterial activity.  Mean weight and thickness data showed that the different
films were uniform. Tensile strength was maximum for drug-free films and minimum for
films containing the highest amount of drug. In vitro drug release data indicate that the films
showed  an  initial  burst  release  followed  by  sustained  release  for  upto  7  days  for
uncrosslinked films (87-95%) and 21 days for crosslinked films (70-78%). Films stored at
refrigerated conditions exhibited slower degradation rate. The drug loaded films that were
crosslinked for 4hrs had inhibitory effect on S. mutans for up to 24 days.
Sujatha et al44, Sparfloxacin dental implants for the treatment of Periodontal diseases was
prepared by using solvent casting technique using hydroxyl propyl cellulose, hydroxyl methyl
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cellulose, eudragit RL-100 and ethyl cellulose with dibutyl phthalate. The drug release was
initially high on day one to achieve immediate therapeutic level of drug in periodontal pocket
followed by marked fall in release by day two with progressive moderate release profile to
maintain  therapeutic  level  following  anamolous  transport  mechanism.  Formulation  F4
released 90.24% of drug at the end of 120hr and was considered as best formulation. In vitro
antibacterial activity was carried out on Streptococcus mutans.
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3. AIM AND OBJECTIVE
     The goal  of  drug delivery system is to  provide a therapeutic  amount of drug to the
targeting  site  in  the  body  to  achieve  promptly  and  then  maintain  the  desired  drug
concentration.
      Our  system of  interest  is  to  develop  Clindamycin  hydrochloride  Implantable  drug
delivery system. This  drug has  low half-life  of  2-3 hrs,  in  order  to  increase its  half-life,
implants were developed.
     Present research work is  to design and evaluate the biodegradable implantable drug
delivery system of Clindamycin hydrochloride for periodontal diseases.
    Thus objective of my work is to formulate and evaluate the implants of Clindamycin
hydrochloride in different  ratios of drug and polymer,  gelatin and sodium alginate and to
study the drug release and anti-microbial activity.
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4. PLAN OF WORK
 Selection of drug and polymer
 Preformulation study
 Formulation of Clindamycin hydrochloride implant in different  drug:polymer ratio
using gelatin and sodium alginate.
 Construction of standard graph of pure drug Clindamycin hydrochloride in 0.1N HCl
and Phosphate buffer pH 7.4.
 Infra red spectroscopy and differential scanning calorimeter analysis for identifying
the interaction between the drug and polymer.
 Physicochemical parameters
Weight uniformity test
Thickness 
Drug content uniformity
Percentage moisture loss
Surface pH
 Invitro drug release studies
 Stability studies
 Antimicrobial activity.
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5.MATERIALS AND METHODS
Table 5.1: Materials used in the formulation
Table 5.2: Equipments
S.N
o
Equipment Manufacturer 
1 IR Shimadzu, Japan
2 Digital balance Essae Teraoka Ltd, India 
3 UV-Visible Lab India, Mumbai.
4 Screw gauge Micrometer, Chennai.
5 Mechanical stirrer Remi Motor Ltd, Mumbai
6 Differential scanning
calorimeter
TA instrument, US.
7 Laminar air flow 
chamber
Klenzaids, Mumbai.
FORMULATION OF CLINDAMYCIN HCl
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Materials                                  Source 
Clindamycin HCl A to Z Pharmaceuticals Private Ltd, Chennai.
 Gelatin Sd fine – chem. Ltd, Mumbai.
Sodium alginate Sd fine – chem. Ltd, Mumbai.
PEG 400 Himedia Laboratories Pvt. Ltd, Mumbai.
Potassium dihydrogen 
phosphate
Spectrum reagents and chemicals Pvt.Ltd, 
Cochin.
Disodium hydrogen phosphate Sd fine – chem. Ltd, Mumbai.
Luria Bertani broth Himedia Laboratories Pvt. Ltd, Mumbai.
Luria Bertani agar Himedia Laboratories Pvt. Ltd, Mumbai.
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       The formulae for the preparation of Clindamycin HCl implants were given in the table 6.
Gelatin and Sodium alginate were used as a polymer.
Aqueous solution of gelatin and sodium alginate combination were prepared by dissolving
them in distilled water by stirring  at a water bath at 60ºC. A solution of drug was added to the
above aqueous solution. The resultant solution was poured on a glass petridish and allowed to
dry at room temperature for 3 days. After drying they were stored at room temperature for
further use. 
The concentration of polymers (gelatin and sodium alginate) was varied i.e., 500 mg, 750 mg
and 1000 mg. In that different concentration of polymers, each had different ratios of gelatin
and sodium alginate 70:30, 80:20 and 90:10 as shown in table 5.
Table 5.3: Polymer ratios used in the formulation
Polymer 500mg
F1 (70:30) F2 (80:20) F3 (90:10)
Gelatin (mg) 350 400 450
Sodium alginate (mg) 150 100 50
Polymer 750mg
F4 (70:30) F5 (80:20) F6 (90:10)
Gelatin (mg) 525 600 675
Sodium alginate (mg) 225 150 75
Polymer 1000mg
F7 (70:30) F8 (80:20) F9 (90:10)
Gelatin (mg) 700 800 900
Sodium alginate (mg) 300 200 100
Preparation of implants
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Soak gelatin in 15ml of distilled water
                                                                                Materials and Methods
                                                                 Hydration, 30minutes
                               Add PEG 400        Heat at 60°C at a water bath
                                                                                         
                                                                              Addition
                                        Drying          3 days at room temperature
Figure 5.1: Method of preparation of Clindamycin HCl implant
Table 5.4: Formulation chart of Clindamycin hydrochloride implants
        Ingredients
                                     
                                      Formulation code
F1 F2 F3 F4 F5 F6 F7 F8 F9
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Add sodium alginate to the gelatin 
solution
Dissolve the drug in 
10ml of distilled water
Stir the solution until it get dissolved
Pour the resultant solution in the glass 
petridish 
Store the dried implant for further 
studies
                                                                                Materials and Methods
Clindamycin
hydrochloride (mg) 250 250 250 250 250 250 250 250 250
Gelatin (mg) 350 400 450 525 600 675 700 800 900
Sodium alginate (mg) 150 100 50 225 150 75 300 200 100
PEG 400 (ml) 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15
Distilled water (ml) 25 25 25 25 25 25 25 25 25
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6. EVALUATION
6.1 PRELIMINARY SCREENING
Drug
i)Melting point
Melting point of the sample was determined by using capillary method.
ii)FTIR spectrum 
FTIR spectrum of  the drug was obtained by preparation of  pellets  using anhydrous  KBr
between 4000 cm-1 and 500 cm-1.
iii)UV scanning
a) Scanning of Clindamycin Hydrochloride in 0.1N HCl
100mg of drug was dissolved in 100ml of 0.1N HCl. 1ml and 5ml of solution was
pipette  and  made  upto  100ml  with  the  0.1N  HCl  to  obtain  10  and  50mg/ml  of
Clindamycin HCl. Scanning was done in the range 200 to 400nm to obtain λmax.
b) Scanning of Clindamycin Hydrochloride in pH 7.4 phosphate buffer
100mg of drug was dissolved in 100ml of pH 7.4 phosphate buffer. 1ml and 5ml of
solution was pipette and made upto 100ml with the pH 7.4 phosphate buffer to obtain
10 and 50mg/ml of Clindamycin HCl. Scanning was done in the range 200 to 400nm
to obtain λmax.
Polymer 
The following polymers were chosen for the formulation of implants.
• HPMC
• MC
• EC
• Gelatin 
• Sodium alginate 
The trial formulation of implant was done with those polymers and the polymer has
been selected. The selected polymer was tested for the compatability studies by using
IR and DSC analysis.
6.2 ANALYTICAL METHODS
Construction of standard curve by UV method
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Preparation of stock solution
100 mg of Clindamycin hydrochloride was accurately weighed and dissolved in 0.1 N HCl.
The  volume  was  made  up  with  the  same  to  produce  100  ml  of  stock  solution  having
concentration of 1 mg/ml. From this 10 ml was pipette out and made up to 100 ml using 0.1
N HCl having concentration of 100 µg/ml.
Preparation of the working standard
  Working standard  solutions  having concentration  of  10  to  60 µg/ml  were  prepared  by
appropriately diluting the stock solution with 0.1 N HCl. The absorbance of each working
standard was measured at 210 nm in UV spectrophotometer using 0.1 N HCl as a reagent
blank.
6.3 DRUG-POLYMER COMPATILIBILITY
6.3.1 IR analysis
 Pure drug and polymers were subjected to IR studies. About 2 mg of pure drug/combination
of drug-polymer were triturated with KBr (Potassium bromide) to form a pellet. The mixture
was placed in the sample holder and was analyzed by infrared to study the interference of
polymers with the drug.
6.3.2 DSC analysis
DSC analysis  was done to  ascertain  the compatibility of  drug with the excipients.It  was
performed on a DSC Q10 V 9.0, differential scanning calorimeter with a thermal analyzer.
About 2.3 mg of the powered sample was placed in a sealed aluminium pan, before heating
under nitrogen flow (20ml/min) at a scanning rate of 10ºC min-1,from 134.98ºC to 148.56ºC.
An empty aluminum pan was used as reference.
6.4 PHYSICOCHEMICAL PARAMETERS
The implants were evaluated for
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 Weight uniformity test
 Thickness of the implants
 Content uniformity
 Percentage of moisture content
 Surface pH
6.4.1 Weight uniformity test45, 46
  The weight uniformity test was carried out by weighing 10 patches cut from different places
of  same  formulation  and  their  individual  weights  were  determined  by  using  the  digital
balance and the average weight was calculated.
                      Table 6.1: Allowable limit for weight variation
Average weight (mg) Maximum % difference allowed
130 or less 10
130-324 7.5
More than 324 5
6.4.2 Thickness of film42
  Film thickness of 10 strips was measured with the help of screw gauge. The strip was placed
between the two jaws and the thickness was measured. The mean value was calculated.
6.4.3 Content uniformity
  The drug content of the prepared implants was estimated using following method. Implant
containing Clindamycin HCl was taken in 100 ml standard volumetric flask. To this pH 7.4
phosphate buffer solution was added and made upto volume. The flask was kept overnight.
The solution was filtered and 5 ml of this filtrate was pipetted out into a 100 ml standard
volumetric flask and made upto the volume with pH 7.4 phosphate buffer solution and the
absorbance was determined at 210 nm.
6.4.4 Percentage moisture loss47
  The percentage moisture loss was carried out to check integrity of the film at dry conditions.
Implant was weighed and kept in a desicator containing anhydrous calcium chloride. After
three days, the implants were taken out and reweighed; the % moisture loss was calculated
using the formula.
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Moisture loss=( Intial weightFinalweight / Initialweight)×100
6.4.5 Surface pH40
  Implant was allowed to  swell  for 1  hour on the surface of  the agar  plate,  prepared by
dissolving 2% w/v agar in warmed distilled water under stirring and then pouring the solution
into the petridish to gelling/solidify at room temperature. The surface pH was measured by
means of pH paper placed on the surface of the swollen film. The mean of 3 readings was
recorded.
6.5 IN-VITRO DRUG RELEASE STUDIES
  The in-vitro release of Clindamycin HCl from the implant was carried out in small test tubes
containing 10 ml of pH 7.4 phosphate buffer. The test tubes were sealed with the aluminium
foil  and  kept  at  37ºC.  The  sample  was  withdrawn  and  replaced  with  the  fresh  pH  7.4
phosphate buffer solution for every 1 hour upto 12th hour. Again the sample was withdrawn at
24th hour. The concentration of drug in the withdrawn solution was measured at 210 nm.
In-vitro drug release kinetic studies48-51
The results of in-vitro release profiles obtained for all the formulations were plotted in modes
of data treatment as follows,
1. Cumulative % drug released versus time (Zero order kinetic model)
2. Log cumulative % drug remaining versus time (First order kinetic model)
3. Cumulative % drug release versus square root of time (Higuchi plot)
4. Log cumulative % drug release versus log T (Koresmeyer-peppas model)
5. Cube root of drug % remaining versus time (Hixson-Crowell model)
Zero Order Kinetics: Zero order release would be predicted by the following equation.
At = A0-K0t
Where, At = Drug released at time ‘t’, A0 = Initial drug concentration
             K0 = Zero order rate constant( h-1)
First Order kinetics: First order release would be predicted by the following equation
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Log C = Log C0 – Kt/2.303
Where, C = Amount of drug remained at time‘t’, C0 = Initial amount of drug
            K= First order rate constant (h-1)
When the data is plotted as log cumulative percent drug remaining versus time it yields a 
straight line , indicating that the release follows first order kinetics. The constant ‘K’ can 
be obtained by multiplying 2.303 with a slope values.
Higuchi Model: In this plot, amount of drug release versus square root of time is plotted. 
The linearity of regression co-efficient determines whether it is being followed or not.
Q= KHt1/2
Where, Q = Amount of drug release at time ‘t’, KH =Higuchi rate constant
Koresmeyer-peppas model: In order to understand the mode of release of drug from 
swellable matrices. The data were fitted to the following peppas law equation
Mt/M = Ktn
Where, Mt/M = Fraction of drug release at time ‘t’
K = Constant incorporating the structural and geometrical characteristics of the 
drug/ polymer system
       n = Diffusion exponent related to the mechanism of the release
when the data is plotted as log of drug released versus log time, a straight line is obtained 
with the slope equal to ‘n’ and the value of ‘K’ can be obtained from y-intercept. For 
fickian release n=0.5 while 0.5<n<1.0 indicates anomalous (Non-fickian) transport and 
n=1 indicates case II diffusion leading to zero-order release.
Hixson-Crowell model: Data obtained from the invitro release studies were plotted cube 
root of % remaining versus time.
W01/3- Wt1/3 = Kt
Where, Wo = Initial amount of drug release at time‘t’, 
       Wt = Remaining amount of drug at time‘t’
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       K = Constant incorporating the surface-volume relation.
6.6 STABILITY STUDIES OF THE OPTIMIZED FORMULATION
Stability is defined as the ability of particular drug or dosage form in a specific container to
remain  with  its  physical,  chemical,  therapeutic  and  toxicological  specifications.  The
optimized formulation was selected for the stability studies.
The purpose of stability testing is to provide evidence on how quality of a drug substance or
drug product varies with time under the influence of a variety of environmental factors such
as  temperature,  humidity  and  light  and  enables  recommended  storage  conditions,  re-test
periods and shelf-lives to be determined. In the present study, stability study is carried out for
the optimized formulation sealed and packed in aluminium foil at room temperature in dark
place and exposure to direct sunlight for one month.
6.7 ANTIMICROBIAL ACTIVITY
6.7.1 Minimum inhibitory concentration52
Add 100 µl of Clindamycin solution (100 µg/100 µl) to the first tube.  Add 4.0 ml of sterile
LB broth to the first tube and add 2.0ml to all other tubes.Transfer 2.0 ml of Luria Bretani
broth from the first tube to the second tube. Using a separate pipette, mix the contents of this
tube and transfer 2.0 ml to the third tube. Continue dilutions in this manner to tube number 4.
Remove 2.0 ml from tube 4 and discard it. The fifth tube, which serves as a control, receives
no Clindamycin. Add 20 µl of the bacterial culture to each of the tubes. Incubate all tubes at
37oC for overnight. Finally read the turbidity using spectrophotometry at 600 nm.
6.7.2 Disc-diffusion method52
Luria Bertani agar medium were prepared and the test micro-organisms were inoculated by
the spread plate method. Filter paper disc were soaked with 2, 4 and 6µg of the Clindamycin
implant  and  placed  in  the  prepared  agar  plates.  Each  disc  was  pressed  down  to  ensure
complete contact with the agar surface and distributed evenly so that they are no closer than
24mm from each other, center to center. The agar plates were then incubated at 37°C. After
16 to 18hrs of incubation, each plate was examined. The resulting zones of inhibition were
uniformly circular with a confluent lawn of growth. The diameter of the zone of complete
inhibition was measured.
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6.7.3 Agar well diffusion method52
Petriplates containing 20ml Luria Bertani agar medium were seeded with 24hrs culture of
bacterial strains. Wells were cut and 2.5, 25, 50, 100 and 200µg of the liquid clindamycin
implant  were added.  The plates were then incubated at  37°C for  24hrs.  The antibacterial
activity was assayed by measuring the diameter of the inhibition zone formed around the
well.
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7. RESULT AND DISCUSSION
7.1 PRELIMINARY SCREENING
Drug
i)Melting point
Melting point was found to be 141.8°C. This complies with melting point reported in USP.
ii)FTIR
The obtained IR spectrum of the sample shows all the prominent and primary peaks and
confirms Clindamycin HCl.
iii)UV scanning
a) Scanning of Clindamycin Hydrochloride in 0.1N HCl
The  prepared  solution  of  Clindamycin  HCl  in  0.1N  HCl  was  scanned  in  UV
spectrophotometer and λmax was found to be 210nm.
b) Scanning of Clindamycin Hydrochloride in pH 7.4 phosphate buffer
The prepared solution of Clindamycin HCl in pH 7.4 phosphate buffer was scanned in
UV spectrophotometer and λmax was found to be 210nm.
                    Figure 7.1: λmax of Clindamycin HCl in 0.1N HCl
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                 Figure 7.2: λmax of Clindamycin HCl in pH 7.4 phosphate buffer
Polymer 
The implant had formulated with the selected polymers and the results was shown in the
following table 7.1
Table 7: Selection of polymer
Trials Inference
Drug+EC No implant was formed
Drug+EC+HPMC No implant was formed
Drug+MC No implant was formed
Drug+gelatin No implant was formed
Drug+sodium alginate No implant was formed
Drug+gelatin+sodium alginate Implant was formed
From the obtained result, implant was not formed with some polymer due to the solubility
nature of the polymers. It was not soluble with the drug during the formulations. Gelatin and
sodium alginate was soluble in the drug solution. The trial with gelatin and sodium alginate
was done by using different ratios and 70:30, 80:20, 90:10 were selected for the formulations.
Further, compatibility study was done by using IR and DSC analysis.
7.2 ANALYTICAL METHOD
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7.2.1 Standard curve of Clindamycin HCl in 0.1N HCl
Beer’s law was found to be obeyed in the concentration range of 10-60 µg/ml with slope
value of 0.005 and correlation coefficient was found to be R2=0.992. The absorbance values
of the working solution in 0.1 N HCl are shown in table no.7.1
  Table 7.1: Preparation of standard curve of Clindamycin hydrochloride in 0.1N HCl
Concentration(µg/ml
)
Absorbance
10 0.049
20 0.103
30 0.154
40 0.221
50 0.240
60 0.303
Figure 7.3: Standard curve for Clindamycin HCl in 0.1N HCl
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7.2.2 Standard  curve of Clindamycin HCl in pH 7.4 buffer
Using the same method calibration curve is plotted in pH 7.4 phosphate buffer. Beer’s law
was found to be obeyed in the concentration range of 10-60 µg/ml with slope value of 0.007
and correlation coefficient was found to be R2=0.995. The absorbance values of the working
solutions in pH 7.4 phosphate buffer are shown in table no.7.2
Table 7.2: Preparation of standard curve of Clindamycin hydrochloride in pH 7.4 buffer
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Concentration(µg/ml) Absorbance
10 0.089
20 0.147
30 0.218
40 0.298
50 0.358
60 0.415
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Figure 7.4: Standard curve for Clindamycin HCl in pH 7.4 buffer
7.3 DRUG-POLYMER COMPATABILITY
7.3.1 IR analysis
Clindamycin HCl and formulation was subjected for IR spectroscopic analysis, to ascertain whether
there is any interaction between the drug and polymers used. The IR spectra obtained are given in
figure 7.5 & 7.6 .The characteristic peak of the pure drug were compared with the peaks obtained for
formulation and are given in the table 10. From the data, it was observed that similar characteristic
peaks  at  3379.4,  2959.87,  1451.48,  1683.91,  1255.7,  1081.14  and  714.65cm-1 for  Clindamycin
implants. It appears that there is no chemical interaction between the drug and polymer.
Table 7.3: IR spectral data of pure drug alone and formulation containing Clindamycin HCl
Group Frequency of pure drug (cm-1) Frequency of formulation (cm-1)
N-H Streching 2947.33 2959.87
C-H bending 1447.62 1451.48
N-H stretching 3375.54 3379.4
C=O stretching 1679.09 1683.91
C-Cl stretching 793.73 714.65
C-C stretching 1251.84 1255.7
C-O stretching 1093.67 1081.14
Hence it can be concluded that the drug is in free state and there is no interaction between drug and
polymers used.
7.3.2 DSC analysis
In order to investigate the possible  interactions between the drug and polymers  used,  differential
scanning calorimetric study as carried out. DSC thermogram of the formulation was compared with
the  pure  drug.  The  DSC  thermograms  obtained  are  reported  in  Figure  7.7  &  7.8.  The  pure
Clindamycin HCl  displayed a sharp endothermic peak at 144.21°C corresponding to the melting
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point  of  the  drug  and  a  similar  peak  was  also  observed  in  the  formulation.  From  the  DSC
thermograms it was observed that the decomposition temperature of the pure drug and the formulation
remained the same. Hence it can be concluded that there was no significant interaction between drug
and the polymers used.
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Figure 7.7: Thermogram of pure Clindamycin hydrochloride
Figure 7.8: Thermogram of Clindamycin HCl with gelatin and sodium alginate
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7.4 PHYSICOCHEMICAL PARAMETERS
7.4.1 Weight uniformity test
                 Table 7.4: Weight uniformity of the Clindamycin HCl  implant
Formulation code Weight of implants(mg) 
F1 0.017±0.001 
F2 0.020±0.002 
F3 0.021±0.002 
F4 0.025±0.002 
F5 0.027±0.002 
F6 0.026±0.002 
F7 0.033±0.003 
F8 0.029±0.003 
F9 0.032±0.003 
n=10
Drug loaded films were tested for uniformity of weight. The weight was found to be uniform
in the prepared batches.
7.4.2 Thickness of the implants
Table 7.5: Thickness of the Clindamycin HCl implant
Formulation code Thickness (mm) 
F1 0.114±0.0156
F2 0.1±0.01
F3 0.131±0.0074
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F4 0.142±0.0104
F5 0.134±0.0112
F6 0.133±0.011
F7 0.169±0.015
F8 0.16±0.0132
F9 0.159±0.0132
n=10
Drug loaded implants were tested for thickness. From the result it was inferred that F1 has
least thickness where as the F7 has a highest thickness since it contain highest concentration
of polymer in the ratio 70:30, 700mg and 300mg of gelatin and sodium alginate respectively.
7.4.3 Content uniformity
 Table 7.6: Content uniformity of the Clindamycin HCl
Formulation
code
Trial I (mg) Trial II (mg) Trial III (mg) Average (mg)
F1 10.53 11.56 11.33 11.14±0.40
F2 11.50 11.53 11.30 11.44±0.09
F3 11.50 11.60 11.43 11.51±0.06
F4 11.01 11.46 11.21 11.22±0.15
F5 11.37 10.07 11.05 10.83±0.50
F6 9.93 11.50 11.40 10.94±0.67
F7 11.54 11.51 11.44 11.49±0.04
F8 11.43 11.45 11.53 11.47±0.12
F9 11.48 11.50 11.43 11.47±0.11
The  test  for  content  uniformity  was  carried  out  to  ascertain  that  the  drug  is  uniformly
distributed into formulation. 
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7.4.4 Percentage moisture loss
Table 7.7: % Moisture loss of the Clindamycin HCl implants
Formulation code Trial I Trial II Average 
F1 28% 37.5% 32.75%
F2 50% 42.85% 46.42%
F3 25% 31.80% 28.4%
F4 26.47% 33.33% 29.9%
F5 25.71% 16.13% 20.92%
F6 16.6% 21.62% 19.11%
F7 20% 17.64% 18.82%
F8 19.35% 22.85% 21.1%
F9 21.73% 16.66% 19.19%
From the result  it  was inferred that  F2 has  highest  moisture loss whereas F7 has  lowest
moisture loss. If gelatin concentration increases moisture loss decreases, since gelatin has low
moisture content.
7.4.5 Surface pH
Table 7.8: Surface pH of the Clindamycin HCl implant
Formulation
code
Trial I Trial II Trial III Average
F1 6 6 6 6
F2 6 6 6 6
F3 6 6 6 6
F4 7 6 7 6.6
F5 7 6 6 6.3
F6 7 7 6 6.6
F7 7 6 7 6.6
F8 6 7 7 6.6
F9 7 7 6 6.6
The surface pH of all formulations was within the range of 6-7 which is close to the neutral
pH and hence no irritation was expected. 
7.4 INVITRO DRUG RELEASE STUDIES
The invitro result of all formulations was carried out in Phosphate buffer pH 7.4. The results
are shown in the table 7.9
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Table 7.9: In-vitro release data of Clindamycin HCl implants of different formulations
Time
in hrs
                                               Formulation code
F1 F2 F3 F4 F5 F6 F7 F8 F9
1 22.84 23.40 23.96 20.46 22.68 23.20 20.12 21.38 22.06
2 26.01 27.13 28.61 24.41 27.89 30.20 23.01 24.20 24.79
3 44.20 44.76 48.01 26.29 29.41 33.58 32.62 37.61 38.24
4 49.17 54.02 56.27 31.34 34.22 37.63 41.86 43.81 45.43
5 55.11 59.45 63.48 37.85 39.82 41.00 49.43 53.62 55.75
6 59.63 63.52 66.95 43.04 47.61 51.72 54.18 59.56 59.76
7 71.50 75.35 79.67 50.82 54.28 57.47 59.74 62.24 63.69
8 79.87 80.12 81.88 57.63 62.08 63.46 61.64 67.37 68.52
9 85.29 87.45 91.52 62.68 65.85 69.87 68.47 74.97 76.91
10 96.21 97.71 98.23 73.67 76.43 78.57 72.68 78.79 80.20
11 - - - 79.53 81.44 82.72 75.53 81.50 83.91
12 - - - 91.14 92.98 94.38 79.78 82.62 85.13
24 - - - 94.71 96.41 97.27 84.90 87.73 89.77
Figure 7.9: In-vitro drug release of the formulation F1, F2 and F3
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Figure 7.10: In-vitro drug release of the formulation F4, F5 and F6
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Figure 7.11: In-vitro drug release of the formulation F7, F8 and F9
From the obtained results, the F1, F2, F3 formulations release the drug 96.21, 97.71, 98.23
respectively at 10th hour due to the presence of low polymer concentration.
In the F4, F5, F6 formulation the release of the drug was 94.71, 96.41, 97.27 respectively at
24th hour because the polymer concentration is  increased when compared with the F1-F3
formulations.
The polymer concentration again increased to sustain the drug release in the formulations F7,
F8, F9 and its release rate was found to be 84.90, 87.73, 89.77 respectively. By increasing the
polymer concentration , the drug release can be sustained.
In-vitro drug release kinetics
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7.5.1 Formulation No.1
Table 7.10: Kinetics data of invitro drug release for F1
Time
in
hrs
log T Square
root  of
T
Cumulativ
e  %drug
release
Log
cumulativ
e  %drug
release
%drug
remaining
Log
%drug
remaining
Cube root
of  drug
%
remainin
g
0 0 0 0 0 0 0 0
1 0 1 22.84 1.358 77.16 1.887 4.327
2 0.301
0
1.414 26.01 1.415 73.99 1.867 4.198
3 0.477
1
1.732 44.20 1.645 55.80 1.746 3.821
4 0.602
0
2 49.17 1.691 50.83 1.706 3.704
5 0.698
9
2.236 55.11 1.741 44.89 1.652 3.553
6 0.778
1
2.449 59.63 1.775 40.37 1.606 3.430
7 0.845
0
2.645 71.50 1.854 28.50 1.454 3.054
8 0.903
0
2.828 79.87 1.902 20.13 1.303 20.720
9 0.954
2
3 85.29 1.930 14.71 1.167 2.450
10 1 3.162 96.21 1.983 3.79 0.578 1.559
11 1.041
3
3.316 - - - - -
12 1.079
1
3.464 - - - - -
24 1.380
2
4.898 - - - - -
7.5.2 Formulation No: 2
Table 7.11: Kinetics data of invitro drug release for the F2
Time log T Square Cumulativ Log %drug Log Cube
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in
hrs
root  of
T
e  %drug
release
cumulativ
e  %drug
release
remainin
g
%drug
remainin
g
root  of
drug  %
remainin
g
0 0 0 0 0 0 0 0
1 0 1 23.40 1.369 76.60 1.884 4.246
2 0.301
0
1.414 27.13 1.433 72.87 1.862 4.176
3 0.477
1
1.732 44.76 1.650 55.24 1.742 3.808
4 0.602
0
2 54.02 1.732 45.98 1.662 3.582
5 0.698
9
2.236 59.45 1.774 40.55 1.607 3.435
6 0.778
1
2.449 63.52 1.802 36.48 1.562 3.316
7 0.845
0
2.645 75.35 1.877 24.65 1.391 2.910
8 0.903
0
2.828 80.12 1.903 19.88 1.298 2.708
9 0.954
2
3 87.45 1.941 12.55 1.098 2.323
10 1 3.162 97.71 1.989 2.29 0.359 1.318
11 1.041
3
3.316 - - - - -
12 1.079
1
3.464 - - - - -
24 1.380
2
4.898 - - - - -
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7.5.3 Formulation No: 3
Table 7.12: Kinetics data of invitro drug release for the F3
Time
in
hrs 
log T Square
root  of
T
Cumulativ
e  %drug
release
Log
cumulativ
e  %drug
release
%drug
remainin
g
Log
%drug
remainin
g
Cube
root  of
drug  %
remainin
g
0 0 0 0 0 0 0 0
1 0 1 23.96 1.379 76.04 1.881 4.236
2 0.301
0
1.414 28.61 1.456 71.39 1.853 4.148
3 0.477
1
1.732 48.01 1.681 51.99 1.715 3.732
4 0.602
0
2 56.27 1.750 43.73 1.640 3.523
5 0.698
9
2.236 63.48 1.802 36.52 1.562 3.317
6 0.778
1
2.449 66.95 1.825 33.05 1.519 3.209
7 0.845
0
2.645 79.67 1.901 20.33 1.308 2.729
8 0.903
0
2.828 81.88 1.913 18.12 1.258 2.626
9 0.954
2
3 91.52 1.961 8.48 0.928 2.039
10 1 3.162 98.23 1.992 1.77 0.247 1.209
11 1.041
3
3.316 - - - - -
12 1.079
1
3.464 - - - - -
24 1.380
2
4.898 - - - - -
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7.5.4 Formulation No: 4
Table 7.13: Kinetics data of invitro drug release for the F4
Time
in
hrs 
log T Square
root  of
T
Cumulativ
e  %drug
release
Log
cumulativ
e  %drug
release
%drug
remainin
g
Log
%drug
remainin
g
Cube
root  of
drug  %
remainin
g
0 0 0 0 0 0 0 0
1 0 1 20.46 1.310 79.54 1.900 4.300
2 0.301
0
1.414 24.41 1.387 75.59 1.878 4.228
3 0.477
1
1.732 26.29 1.419 73.71 1.867 4.192
4 0.602
0
2 31.34 1.496 68.66 1.836 4.094
5 0.698
9
2.236 37.85 1.578 62.15 1.793 3.961
6 0.778
1
2.449 43.04 1.633 56.96 1.755 3.847
7 0.845
0
2.645 50.82 1.706 49.18 1.691 3.663
8 0.903
0
2.828 57.63 1.760 42.37 1.627 3.486
9 0.954
2
3 62.68 1.797 37.32 1.571 3.341
10 1 3.162 73.67 1.867 26.33 1.420 2.974
11 1.041 3.316 79.53 1.900 20.47 1.311 2.735
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3
12 1.079
1
3.464 91.14 1.959 8.86 0.947 2.069
24 1.380
2
4.898 94.71 1.976 5.29 0.723 1.742
7.4.5 Formulation No: 5
Table 7.14: Kinetics data of the invitro drug release for F5
Time
in
hrs
log T Square
root  of
T
Cumulativ
e  %drug
release
Log
cumulativ
e  %drug
release
%drug
remainin
g
Log
%drug
remainin
g
Cube
root  of
drug  %
remainin
g
0 0 0 0 0 0 0 0
1 0 1 22.68 1.355 77.32 1.888 4.260
2 0.301
0
1.414 27.89 1.445 72.11 1.857 4.162
3 0.477
1
1.732 29.41 1.468 70.59 1.848 4.132
4 0.602
0
2 34.22 1.534 65.78 1.818 4.036
5 0.698
9
2.236 39.82 1.600 60.18 1.779 3.918
6 0.778
1
2.449 47.61 1.677 52.39 1.719 3.741
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7 0.845
0
2.645 54.28 1.734 45.72 1.660 3.575
8 0.903
0
2.828 6208 1.792 37.92 1.578 3.359
9 0.954
2
3 65.85 1.818 34.15 1.533 3.244
10 1 3.162 76.43 1.883 23.57 1.372 2.867
11 1.041
3
3.316 81.44 1.910 18.56 1.268 2.647
12 1.079
1
3.464 92.98 1.968 7.02 0.846 1.914
24 1.380
2
4.898 96.41 1.984 3.59 0.555 1.531
7.4.6 Formulation No: 6
Table 7.15: Kinetics data of the invitro drug release for the F6
Time
in
hrs
log T Square
root  of
T
Cumulativ
e  %drug
release
Log
cumulativ
e  %drug
release
%drug
remainin
g
Log
%drug
remainin
g
Cube root
of  drug
%
remaining
0 0 0 0 0 0 0 0
1 0 1 23.20 1.365 76.80 1.885 4.250
2 0.301
0
1.414 30.20 1.480 69.80 1.843 4.117
3 0.477 1.732 33.58 1.526 66.42 1.822 4.049
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1
4 0.602
0
2 37.63 1.575 62.37 1.794 3.965
5 0.698
9
2.236 41.00 1.612 59.00 1.770 3.892
6 0.778
1
2.449 51.72 1.713 48.28 1.683 3.641
7 0.845
0
2.645 57.47 1.759 42.53 1.628 3.490
8 0.903
0
2.828 63.46 1.802 36.54 1.562 3.318
9 0.954
2
3 69.87 1.844 30.13 1.478 3.111
10 1 3.162 78.57 1.895 21.43 1.331 2.777
11 1.041
3
3.316 82.72 1.917 17.28 1.237 2.585
12 1.079
1
3.464 94.38 1.974 5.62 0.749 1.777
24 1.380
2
4.898 97.27 1.987 2.73 0.430 1.397
7.5.7 Formulation No: 7
Table 7.16: Kinetics data of the invitro drug release for  F7
Time
in
log T Square
root  of
Cumulativ
e  %drug
Log
cumulativ
%drug
remainin
Log
%drug
Cube
root  of
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hrs T release e  %drug
release
g remainin
g
drug  %
remainin
g
0 0 0 0 0 0 0 0
1 0 1 20.12 1.303 79.88 1.902 4.306
2 0.301
0
1.414 23.01 1.361 76.99 1.886 4.254
3 0.477
1
1.732 32.62 1.513 67.38 1.828 4.069
4 0.602
0
2 41.86 1.621 58.14 1.764 3.873
5 0.698
9
2.236 49.43 1.693 50.57 1.703 3.697
6 0.778
1
2.449 54.18 1.733 45.82 1.661 3.578
7 0.845
0
2.645 59.74 1.776 40.26 1.604 3.427
8 0.903
0
2.828 61.64 1.789 38.36 1.583 3.372
9 0.954
2
3 68.47 1.835 31.53 1.498 3.159
10 1 3.162 72.68 1.861 27.32 1.436 3.011
11 1.041
3
3.316 75.53 1.878 24.47 1.388 2.903
12 1.079
1
3.464 79.78 1.901 20.22 1.305 2.724
24 1.380
2
4.898 84.90 1.928 15.10 1.178 2.471
Figure 7.12: Zero-order release kinetics for the formulation F7
Department of Pharmaceutics, RVS College of Pharmaceutical Sciences Page 64
C
u
m
u
la
ti
v
e
 %
d
ru
g
 r
e
le
a
se
                                                                                   Result and Discussion
Figure 7.13: First-order release kinetics for the formulation F7
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Figure 7.14: Higuchi release kinetics for the formulation F7
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Figure 7.15: Koresmeyer-peppas release kinetics for the formulation F7
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Figure 7.16: Hixson-Crowell release kinetics for the formulation F7
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7.5.8 Formulation No: 8
Table 7.17: Kinetics data of the invitro drug release for F8
Time
in
hrs
log T Square
root  of
T
Cumulativ
e  %drug
release
Log
cumulativ
e  %drug
release
%drug
remainin
g
Log
%drug
remainin
g
Cube
root  of
drug  %
remainin
g
0 0 0 0 0 0 0 0
1 0 1 21.38 1.330 78.62 1.895 4.283
2 0.301
0
1.414 24.20 1.383 75.80 1.876 4.232
3 0.477
1
1.732 37.61 1.575 62.39 1.795 3.966
4 0.602
0
2 43.81 1.641 56.19 1.749 3.830
5 0.698
9
2.236 53.62 1.729 46.38 1.666 3.592
6 0.778
1
2.449 59.56 1.774 40.44 1.606 3.432
7 0.845
0
2.645 62.24 1.794 37.76 1.577 3.354
8 0.903
0
2.828 67.37 1.828 32.63 1.513 3.195
9 0.954
2
3 74.97 1.874 25.03 1.398 2.925
10 1 3.162 78.79 1.896 21.21 1.326 2.768
11 1.041
3
3.316 81.50 1.911 18.50 1.267 2.644
12 1.079 3.464 82.62 1.917 17.38 1.240 2.590
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1
24 1.380
2
4.898 87.73 1.943 12.27 1.088 2.306
7.5.9 Formulation No: 9
Table 7.18: Kinetics data of the invitro drug release for F9
Time
in
hrs
log T Square
root  of
T
Cumulativ
e  %drug
release
Log
cumulativ
e  %drug
release
%drug
remainin
g
Log
%drug
remainin
g
Cube
root  of
drug  %
remainin
g
0 0 0 0 0 0 0 0
1 0 1 22.06 1.343 77.94 1.891 4.271
2 0.301
0
1.414 24.79 1.394 75.21 1.876 4.221
3 0.477
1
1.732 38.24 1.582 61.76 1.790 3.952
4 0.602
0
2 45.43 1.657 54.57 1.736 3.793
5 0.698
9
2.236 55.75 1.746 44.25 1.645 3.537
6 0.778
1
2.449 59.76 1.776 40.24 1.604 3.426
7 0.845
0
2.645 63.69 1.804 36.31 1.560 3.311
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8 0.903
0
2.828 68.52 1.835 31.48 1.498 3.157
9 0.954
2
3 76.91 1.885 23.09 1.363 2.847
10 1 3.162 80.20 1.904 19.80 1.296 2.705
11 1.041
3
3.316 83.91 1.923 16.09 1.266 2.524
12 1.079
1
3.464 85.13 1.930 14.87 1.172 2.459
24 1.380
2
4.898 89.77 1.953 10.23 1.009 2.170
From the various mathematical models, the in-vitro kinetics studies were performed for all
the formulations.  The ‘n’ value was in the range 0.87-0.93. So that  the prepared implant
undergo diffusion mechanism because it follows non-fickian or anamolous transport.
7.6 COMPARATIVE KINETICS OF ALL THE FORMULATIONS
The comparative kinetics value for zero-order, first-order, higuchi, koresmeyer-peppas and
Hixson-crowell are shown in the following tables and figures.
Table 7.19: Comparative kinetics for Zero-order drug release kinetics
Formulation
code
Zero-Order Drug Release
R2 K0
F1 0.973 10.09
F2 0.968 11.42
F3 0.959 12.81
F4 0.812 18.95
F5 0.801 21.81
F6 0.789 24.03
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 F7 0.725 26.88
F8 0.696 28.75
F9 0.696 29.46
                                                             
Figure 7.17: Comparative kinetics of Zero-order for the formulation F1, F2 and F3
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Figure 7.18: Comparative kinetics of Zero-order for the formulation F4, F5 and F6
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Figure 7.19: Comparative kinetics of Zero-order for the formulation F7, F8 and F9
Table 7.20: Comparative kinetics for First-order kinetics
Formulation
code
First-Order Drug Release
R2 K1
F1 0.014 1.468
F2 0.030 1.482
F3 0.057 1.495
F4 0.098 1.656
F5 0.142 1.662
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F6 0.178 1.663
F7 0.005 1.534
F8 0.022 1.517
F9 0.038 1.519
Figure 7.20: Comparative kinetics of First-order for the formulation F1, F2 and F3
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Figure 7.21: Comparative kinetics of First-order for the formulation F4, F5 and F6
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Figure 7.22: Comparative kinetics of First-order for the formulation F7, F8 and F9
Table 7.21: Comparative kinetics for Higuchi release kinetics
Formulation
code
Higuchi  Drug Release
R2 KH
F1 0.965 0.048
F2 0.974 0.070
F3 0.979 0.093
F4 0.915 0.063
F5 0.923 0.071
F6 0.929 0.076
F7 0.932 0.026
F8 0.917 0.035
F9 0.917 0.041
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Figure 7.23: Comparative kinetics of Higuchi for the formulation F1, F2 and F3
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Figure 7.24: Comparative kinetics of Higuchi for the formulation F4, F5 and F6
Department of Pharmaceutics, RVS College of Pharmaceutical Sciences Page 79
C
u
m
u
la
ti
v
e
%
 d
ru
g
 r
e
le
a
se
                                                                                   Result and Discussion
Figure 7.25: Comparative kinetics of Higuchi for the formulation F7, F8 and F9
Table 7.22: Comparative kinetics for Koresmeyer-peppas drug release kinetics
Formulation
code
Koresmeyer-peppas Drug Release
R2 Kkp
F1 0.648 0.829
F2 0.644 0.841
F3 0.640 0.855
F4 0.668 0.836
F5 0.641 0.876
F6 0.519 0.991
F7 0.636 0.883
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F8 0.625 0.908
F9 0.622 0.917
Figure 7.26: Comparative kinetics of Koresmeyer-peppas for the formulation F1, F2
and F3
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Figure 7.27: Comparative kinetics of Koresmeyer-peppas for the formulation F4, F5
and F6
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Figure 7.28: Comparative kinetics of Koresmeyer-peppas for the formulation F7, F8
and F9
Table 7.23: Comparative kinetics for Hixson-Crowell drug release kinetics
Formulation
code
Hixson-Crowell Drug Release
R2 KHC
F1 0.015 0.048
F2 0.033 0.070
F3 0.056 0.093
F4 0.100 0.063
F5 0.125 0.071
F6 0.143 0.076
F7 0.022 0.026
F8 0.038 0.035
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F9 0.054 0.041
Figure 7.29: Comparative kinetics of Hixson-Crowell for the formulation F1, F2 and F3
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Figure 7.30: Comparative kinetics of Hixson-Crowell for the formulation F4, F5 and F6
Figure 7.31: Comparative kinetics of Hixson-Crowell for the formulation F7, F8 and F9
7.6 STABILITY STUDIES
Stability studies of the optimized formulations of Clindamycin implants was carried out to
determine the effect of formulation additives on the stability of the drug and also to determine
the physical  stability of  the formulations.  The stability studies  were  carried out  at  room
temperature 29ºC, dark place and direct sunlight.
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Stability  studies  showed after  one  month  the  significant  changes  in  the  physicochemical
parameters and drug release was shown in the table 31.
Table 7.24: Stability studies data of the optimized formulation of Clindamycin implants
S.N
o
      Parameter 
Stability studies
0th day 30th day
Room
temp.
29ºC
Dark
place
Direct
sunligh
t
Room
temp.
29ºC
Dark
place
Direct
sunligh
t
1 Weight uniformity 0.032 0.028 0.026 0.030 0.025 0.020
2 Thickness 0.165 0.166 0.152 0.162 0.164 0.150
3 % Moisture loss 16.6% 19.01% 18.21% 16.05
%
18.89
%
17.65%
4 Surface pH 7 6 7 7 6 7
5 Drug content 11.62 11.48 11.29 11.61 11.45 11.05
6 Drug  release  at  24th
hour
85.96% 84.97% 85.69% 86.23
%
85.60
%
90.25%
Stability studies were conducted on implants at room temperature, dark place and exposure to
direct sunlight for one month. The observed parameters reduced markedly after exposing to
direct sunlight and no significant change at room temperature, dark place. The stability of the
drug was improved by formulating them in polymer matrix.
7.7 ANTIMICROBIAL ACTIVITY
7.7.1 Minimum inhibitory concentration
The minimum inhibitory concentration was determined by using different concentration of
the Clindamycin implant in various micro-organisms.
Table 7.25: Minimum inhibitory concentration of Clindamycin HCl
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Organism
name
Control 12.5 µg 25 µg 50 µg 100µg
Klebsiella 0.132 0.113 0.11 0.108 0.084
Salmo 0.15 0.114 0.092 0.087 0.069
SPA 0.143 0.121 0.108 0.097 0.081
SPB 0.138 0.098 0.092 0.085 0.061
Ent.bact 0.109 0.088 0.082 0.071 0.009
Pro mira 0.175 0.114 0.136 0.103 0.093
Staph 0.077 0.008 0.006 0.005 0.004
Kleb  –  Klebsiella  pneumonia;  Salmo-  Salmonella;  SPA-  Salmonella  typhi A;  SPB-
Salmonella  typhi B;  Ent.bact-Enterobacter  aerogens;  Pro  mira-  Proteus  mirabilis;  Staph-
Staphylococcus aureus
    
                           Figure 7.32: MIC of Clindamycin implant in Salmonella
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                        Figure 7.33: MIC of Clindamycin implant in Salmonella paratyphi A
                          Figure 7.34: MIC of Clindamycin implant in Salmonella paratyphi B
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                        Figure 7.35: MIC of Clindamycin implant in Enterobacter aerogens
                     Figure 7.36: MIC of Clindamycin implant in Staphylococcus aureus
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                             Figure 7.37: MIC of Clindamycin implant in Proteus mirabilis 
                            Figure 7.38: MIC of Clindamycin implant in Klebsiella pneumoniae
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7.7.2 Disc diffusion and agar well diffusion method
The diameter of zone of inhibition was measured and the value was shown in the table 7.26.
Table 7.26: Diameter of zone of inhibition of Clindamycin implants
 
ORGANISM
NAME
AGAR WELL DIFFUSION
METHOD
(ZONE SIZE)
DISC DIFFUSION METHOD    
(ZONE SIZE)
12.5µ
g
25µ
g
50 µg 100 
µg
200 
µg
+ive 
Control 
(2 µg)
2 µg 4 µg 16 µg
Staphylococcus 
aureus
6 mm 9mm 11mm 13mm 17 
mm
5 mm 6 mm 7mm 11mm
Enterobacter 
aerogens
4 mm 5mm 7 mm 10 
mm
16 
mm
1 mm 1.5m
m
3 
mm
5 mm
+ive control = Standard Clindamycin disc
After  24hrs  of  incubation,  the  diameter  of  zone  of  inhibition  was  measured  and  it  was
compared with the standard drug diameter. It  shows better antibacterial activity over those
micro-organisms. The zone of inhibition of Clindamycin implant by agar disc diffusion and
agar well diffusion method was shown in the following figures.
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Figure 7.39: Disc diffusion zone for Staphylococcus aureus using Clindamycin  
implant  pad
Figure 7.40: Disc diffusion 
zone for Enterobacter 
aerogens using Clindamycin implant pad
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Figure 7.41: Agar well diffusion method in Staphylococcus aureus using 
Clindamycin liquid
Figure 7.42: Agar well diffusion method in Staphylococcus aureus using 
Clindamycin liquid
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Figure 7.43: Agar well diffusion method in Enterobacter aerogens using 
Clindamycin liquid
Figure 7.44: Agar well diffusion method in Enterobacter aerogens using     
Clindamycin liquid
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8. SUMMARY AND CONCLUSION
Development of implantable drug delivery system is triggered by the need to control the drug
release and for the localized therapy.
Clindamycin  hydrochloride  was  incorporated  in  gelatin  and  sodium alginate  polymer  in
different concentrations. The various physicochemical parameters, drug release studies and
antimicrobial activity were performed for the developed implant.
The following conclusions were drawn from the results obtained.
 In  the  preliminary  screening,  the  drug  undergo  melting  point  determination,  IR
analysis and UVscanning, the result obtained was complied with the USP standards.
 From the FT-IR spectra, it was observed that similar characteristic was observed that
similar peaks appear for the drug and their formulation. Hence, it shows that there was
no chemical interaction between the drug and polymer used.
 The DSC thermograms obtained for the pure drug and for the formulation showed no
significant shift in the endothermic peaks confirming the stability of the drug in the
formulation.
 From the results of the weight uniformity and thickness, it can be inferred that all the
formulations  exhibited  uniform weight  and  thickness  with  low standard  deviation
values.
 All the formulations were found to obtain uniform quantity of drug as per content
uniformity studies indicating reproducibility of the technique.
 For all the formulation, the percentage moisture showed maximum loss except F7
because of low concentration of gelatin undergo moisture loss in dry condition.
 From the result of invitro release studies of the formulation F1 to F9, the formulation
F7 showed an sustained release at the end of 24th hour due to the high concentration of
gelatin and sodium alginate, 700 and 300 mg respectively.
 The  ‘n’ values  of  various  mathematical  model  fittings  suggests  that  all  the  films
exhibit  anamolous  transport.  It  had  concluded  that  the  prepared  implant  undergo
diffusion mechanism
 The  antimicrobial  activities  were  performed  on  Staphylococcus  aureus and
Enterobacter aerogens, the zone of inhibition was observed by agar disc diffusion and
agar  well  diffusion  method.  From the  results,  the optimized  implant  shows better
activity over those micro-organisms.
 The result of stability studies carried out on optimized formulation indicate that after
one month at  room temperature,  dark place and direct  sunlight.  The drug content
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reduced markedly after exposing sunlight and there was no significant change at room
temperature and dark place.
 The future plan is to carry out the invitro-invivo correlation studies.
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